<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782548</url>
  </required_header>
  <id_info>
    <org_study_id>AA20003</org_study_id>
    <nct_id>NCT00782548</nct_id>
  </id_info>
  <brief_title>Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults</brief_title>
  <official_title>A Phase IV, Comparative, Randomized, Double Blind, Single-Dose, 2-Way Crossover Study to Evaluate the Pharmacokinetics and Safety of Alpharma Branded Products Division (KADIAN)and Ligand Pharmaceuticals Inc. (Avinza) 30 mg Morphine Sulfate Sustained-Release Capsules in Healthy Adult Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.</source>
  <brief_summary>
    <textblock>
      The primary objective of this study was to compare the single-dose relative bioavailability
      of Alpharma Branded Products Division (Kadian®) and Ligand® Pharmaceuticals Inc. (AVINZA®) 30
      mg morphine sulfate sustained-release capsules in healthy adult volunteers under fed
      conditions.

      The secondary objective of this study was to evaluate the adverse events associated with each
      of these 2 different morphine sulfate modified-release commercial formulations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma samples analyzed for morphine, morphine-3-glucuronide, and morphine-6-glucuronide</measure>
    <time_frame>60 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the adverse events associated with each of these 2 different morphine sulfate modified-release commercial formulations</measure>
    <time_frame>monitored throughout study, until resolution</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test product A (1 x 30 mg KADIAN)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test product B (1 x 30 mg Avinza)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine sulfate sustained-release capsules</intervention_name>
    <description>Capsules, 30 mg</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy adult non-smoker, or moderate smokers (less than 10 cigarettes per day for at
             least 3 months) or ex-smoker (no smoking for at least 3 months) male or female
             volunteers, 19 to 40 years of age.

          -  Weighing at least 60 kg for males and 52 kg for females and within 15% of their ideal
             weights (Table of &quot;Desirable Weights of Adults&quot;, Metropolitan Life Insurance Company,
             1983).

          -  Medically healthy subjects with no clinically significant abnormalities in their
             laboratory profile and ECGs, as deemed by the Principal Investigator.

          -  Females of childbearing potential should either be sexually inactive (abstinent) for
             14 days prior to the first dose and throughout the study or be using one of the
             following acceptable birth control methods:

               1. surgically sterile (bilateral tubal ligation, hysterectomy, bilateral
                  oophorectomy) 6 months minimum.

               2. IUD in place for at least 3 months;

               3. barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to
                  the first dose and throughout the study;

               4. surgical sterilization of the partner (vasectomy for 6 months minimum);

               5. hormonal contraceptives for at least 3 months prior to the first dose of the
                  study.

        Other birth control methods may have been deemed acceptable. Postmenopausal women with
        amenorrhea for &gt; than 2 year, and confirmed by blood testing.

          -  Voluntarily consent to participate in the study.

        Exclusion criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or
             psychiatric disease.

          -  In addition, history or presence of:

               1. alcoholism or drug abuse within the past 2 years;

               2. asthma or other chronic respiratory illness;

               3. gastrointestinal dysmobility or recent enteritis;

               4. hypersensitivity or idiosyncratic reaction to morphine or other opioids;

               5. hypersensitivity or idiosyncratic reaction to naltrexone, naloxone, or other
                  narcotic antagonists.

          -  Female subjects who were pregnant or lactating.

          -  Subjects who had a surgery of the gastrointestinal tract (except appendectomy) which
             would interfere with absorption of the study drug

          -  Subjects who received hepatic enzyme inducing drugs (e.g. Nizoral®, Tagamet®) within
             the previous three months

          -  Subjects whose sitting blood pressure was less than 110/60 mm Hg at screening or
             100/55 mm Hg before dosing.

          -  Subjects who were on a special diet (for whatever reason) during the 28 days prior to
             the first dose and throughout the study.

          -  Subjects who had made a donation (standard donation amount or more) of blood or blood
             products (with the exception of plasma as noted below) within 56 days prior to the
             study.

          -  Subjects who had made a plasma donation within 7 days prior to the study.

          -  Subjects with hemoglobin less than 12.0 g/dL.

          -  Subjects who had participated in another clinical trial within 28 days prior to the
             first dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan S. Marion, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>October 29, 2008</last_update_submitted>
  <last_update_submitted_qc>October 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Alan S. Marion, MD, PhD</name_title>
    <organization>MDS Pharma Services</organization>
  </responsible_party>
  <keyword>KADIAN</keyword>
  <keyword>morphine</keyword>
  <keyword>Avinza</keyword>
  <keyword>30 mg</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>fed</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 8, 2008</submitted>
    <returned>January 6, 2009</returned>
    <submitted>July 21, 2009</submitted>
    <returned>August 31, 2009</returned>
    <submitted>November 18, 2009</submitted>
    <returned>December 15, 2009</returned>
    <submitted>December 15, 2009</submitted>
    <returned>January 15, 2010</returned>
    <submitted>August 13, 2010</submitted>
    <returned>September 8, 2010</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

